How I treat chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists.
Hanny Al-Samkari, Gerald A Soff
✦ AI-curated · Sources linked
Case in brief
The article discusses four cases of chemotherapy-induced thrombocytopenia (CIT), highlighting the complexities of managing this condition. It emphasizes the importance of understanding the two clinical subtypes of CIT—persistent and nadir—and the limited efficacy of platelet transfusions. The cases illustrate the impact of thrombopoietin receptor agonists (TPO-RAs) on patient outcomes when appropriately selected and monitored.
Diagnostic / clinical pearl
Clinicians should recognize the distinct subtypes of chemotherapy-induced thrombocytopenia and the role of thrombopoietin receptor agonists in managing patients who require treatment.
Why it matters
Effective management of CIT can significantly influence chemotherapy dosing and overall patient outcomes, underscoring the need for tailored treatment strategies.